Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa

Inclusion Criteria

• •Diagnosis of HS or signs and symptoms consistent with HS for at least 3 months before screening in the judgment of the investigator.
• •Stable disease for at least 2 months before screening in the judgment of the investigator.
• •A woman of childbearing potential must use appropriate contraceptive measures during the study period.
• •A woman of childbearing potential must have a negative urine pregnancy test result at screening.
• •Written informed consent must be obtained before any study procedure is performed.